Action AVEO Pharmaceuticals - AVEO

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

15,00

Prix Achat

14,99

Prix Vente

15,00

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

15,00

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief...

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief...

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology, an LG Chem company (“AVEO”), today announced The...

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Phase 3 Registrational Trial Seeks to Improve Survival Outcomes in Underserved HPV-negative R/M Head and Neck...

LG Chem Completes Acquisition of AVEO Oncology

SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today...

AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C...

AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside...

AVEO Oncology Announces Presentation of Key Subgroup & Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in...

– Data Presented at the ASCO 2021 GU Cancers Symposium – –Sequencing Data Support Tivozanib is a Differentiated Selective VEGF TKI; Q-TWiST...

AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Faci...

– $20M Tranche Available on Approval of Tivozanib – AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an...

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI...

– Data Presented at the 2021 ASCO GI Cancers Symposium – AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

AVEO - Frequently Asked Questions (FAQ)

What is the current AVEO Pharmaceuticals share price?

The current share price of AVEO Pharmaceuticals is US$ 15,00

What is the 1 year trading range for AVEO Pharmaceuticals share price?

AVEO Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ARBBARB IOT Group Ltd	US$ 0,9345 (79,71%)	10,25M
TLFTandy Leather Factory Inc	US$ 4,14 (34,85%)	4
HNVRHanover Bancorp Inc	US$ 29,99 (27,73%)	3
BHFBrighthouse Financial Inc	US$ 69,99 (27,35%)	13
GTIGraphjet Technology	US$ 0,175 (26,81%)	24,53M
RETOReTo Eco Solutions Inc	US$ 0,63 (-28,81%)	102,97k
SYRESpyre Therapeutics Inc	US$ 13,13 (-27,94%)	22
OMEROmeros Corporation	US$ 6,01 (-24,69%)	8
ARHSArhaus Inc	US$ 7,01 (-24,30%)	87
GHRSGH Research PLC	US$ 7,21 (-23,22%)	3
NVNINVNI Group Ltd	US$ 0,3313 (26,21%)	32,33M
GTIGraphjet Technology	US$ 0,175 (26,81%)	24,53M
ARBBARB IOT Group Ltd	US$ 0,9345 (79,71%)	10,25M
CGBSCrown LNG Holdings Ltd	US$ 0,2265 (-4,31%)	8,78M
BTOGBit Origin Ltd	US$ 0,415 (15,92%)	8,09M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

AVEO Pharmaceuticals Inc (AVEO)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

AVEO Dernières nouvelles

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

LG Chem Completes Acquisition of AVEO Oncology

AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference

AVEO Oncology Announces Presentation of Key Subgroup & Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in...

AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Faci...

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI...

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

AVEO Pharmaceuticals Inc (AVEO) Cours

AVEO Pharmaceuticals Inc (AVEO)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

AVEO Dernières nouvelles

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

LG Chem Completes Acquisition of AVEO Oncology

AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference

AVEO Oncology Announces Presentation of Key Subgroup & Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in...

AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Faci...

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI...

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS